Insider · CIK 0001750094

Gline Matthew

Reports to the SEC for 2 companies · LONDON

sec.gov

Transactions

Companies

Filings

CIK

0001750094

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-30	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−76.2K sh	$36.57	−$2.79M	16,583,774
2026-06-30	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−76.2K sh	$35.39	−$2.7M	16,659,945
2026-04-16	ROIVRoivant Sciences Ltd.S Sale	Director, CEO	SSale	−290K sh	$29.16	−$8.45M	16,736,116
2026-03-31	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−305K sh	$27.70	−$8.44M	17,025,890
2026-03-30	ROIVRoivant Sciences Ltd. · Capped Value Appreciation RightsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−2.18M sh	$11.50	−$25M	0
2026-03-30	ROIVRoivant Sciences Ltd.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+97.3K sh	—	—	17,384,400
2026-03-30	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−53.8K sh	$26.41	−$1.42M	17,330,574
2025-12-15	ROIVRoivant Sciences Ltd.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+2.27M sh	$12.68	+$28.8M	19,559,933
2025-12-15	ROIVRoivant Sciences Ltd.S Sale	Director, CEO	SSale	−944K sh	$21.68	−$20.5M	18,616,406
2025-12-15	ROIVRoivant Sciences Ltd.J Other	Director, CEO	JOther	−1.33M sh	$21.68	−$28.8M	17,287,081
2025-12-15	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO	MExercise/Conversion	−234K sh	—	—	0
2025-12-15	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO	MExercise/Conversion	−1.36M sh	—	—	0
2025-12-15	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO	MExercise/Conversion	−2.27M sh	—	—	0
2025-12-15	ROIVRoivant Sciences Ltd.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+234K sh	$4.06	+$950K	17,521,177
2025-12-15	ROIVRoivant Sciences Ltd.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+1.36M sh	$12.68	+$17.3M	18,650,792
2025-12-15	ROIVRoivant Sciences Ltd.S Sale	Director, CEO	SSale	−566K sh	$21.68	−$12.3M	18,084,676
2025-12-15	ROIVRoivant Sciences Ltd.J Other	Director, CEO	JOther	−798K sh	$21.68	−$17.3M	17,287,081
2025-12-15	ROIVRoivant Sciences Ltd.J Other	Director, CEO	JOther	−3,739 sh	$21.68	−$81.1K	17,287,081
2025-12-15	ROIVRoivant Sciences Ltd.S Sale	Director, CEO	SSale	−230K sh	$21.68	−$4.99M	17,290,820
2025-09-18	ROIVRoivant Sciences Ltd.P Purchase	Director, CEO	PPurchase	+3,315 sh	$15.07	+$50K	17,287,081
2025-05-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$11.04	−$121K	17,283,766
2025-04-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$10.15	−$111K	17,294,711
2025-03-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$10.97	−$120K	17,305,656
2025-02-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$10.72	−$117K	17,316,601
2025-01-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−11.6K sh	$11.15	−$130K	17,327,546
2024-12-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$11.57	−$127K	17,339,169
2024-11-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$11.49	−$126K	17,350,114
2024-10-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$11.92	−$130K	17,361,059
2024-09-23	ROIVRoivant Sciences Ltd.J Other	Director, CEO	JOther	−499K sh	$11.97	−$5.97M	17,372,004
2024-09-23	ROIVRoivant Sciences Ltd.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+1.55M sh	$3.85	+$5.97M	19,853,800
2024-09-23	ROIVRoivant Sciences Ltd.S Sale	Director, CEO	SSale	−1.98M sh	$11.79	−$23.4M	17,870,543
2024-09-23	ROIVRoivant Sciences Ltd. · Stock Option (Right to Buy)M Exercise/Conversion	Director, CEO	MExercise/Conversion	−1.55M sh	—	—	14,973,184
2024-09-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$11.97	−$131K	18,303,800
2024-08-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$11.48	−$126K	18,314,745
2024-07-26	ROIVRoivant Sciences Ltd.A Award	Director, CEO	AAward	+14.5M sh	—	—	18,325,692
2024-07-26	ROIVRoivant Sciences Ltd.A Award	Director, CEO	AAward	+2.75M sh	—	—	3,875,692
2024-07-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$11.00	−$120K	1,120,871
2024-06-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$10.80	−$118K	1,131,816
2024-05-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$11.37	−$124K	1,142,761
2024-04-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$10.46	−$114K	1,153,706
2024-03-30	ROIVRoivant Sciences Ltd.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+391K sh	—	—	1,380,642
2024-03-30	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−216K sh	$10.54	−$2.28M	1,164,651
2024-03-30	ROIVRoivant Sciences Ltd. · Capped Value Appreciation RightsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−994K sh	$6.40	−$6.36M	0
2024-03-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$10.01	−$110K	990,063
2024-02-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$11.54	−$126K	1,001,008
2024-01-20	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−10.9K sh	$10.35	−$113K	1,011,953
2023-12-27	ROIVRoivant Sciences Ltd. · Capped Value Appreciation RightsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−85.2K sh	$6.40	−$545K	994,373
2023-12-27	ROIVRoivant Sciences Ltd.F Tax Payment	Director, CEO	FTax Payment	−22K sh	$11.58	−$255K	1,022,898
2023-12-27	ROIVRoivant Sciences Ltd.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+38.5K sh	—	—	1,044,941
2023-12-27	ROIVRoivant Sciences Ltd. · Capped Value Appreciation RightsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−47.4K sh	$11.50	−$545K	2,178,150

Recent filings

Accepted (ET)
Oct 24
Gline Matthew0001140361-26-038475
SEC(opens sec.gov)
Jul 24
Gline Matthew0001635088-26-000079
SEC(opens sec.gov)
Apr 204
Gline Matthew0001635088-26-000038
SEC(opens sec.gov)
Apr 14
Gline Matthew0001635088-26-000034
SEC(opens sec.gov)
Dec 174
Gline Matthew0001140361-25-045906
SEC(opens sec.gov)
Sep 184
Gline Matthew0001140361-25-035435
SEC(opens sec.gov)

Companies

Address

C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY

LONDON, SW1H0DB